All In Biotech

Drug Trial Radar · NCT06640517

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Aug 8, 2024

Primary completion

Jun 2026

Study completion Feb 2028

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.

Conditions

  • Plaque Psoriasis

Interventions

  • NetakimabDrug

    netakimab will be administered subcutaneously with induction once a week for the first three weeks, then once every 4 weeks

  • PlaceboDrug

    placebo will be administered subcutaneously at a scheme masking netakimab treatment

  • AdalimumabDrug

    adalimumab will be administered subcutaneously at weeks 1, 2, and then once every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving PASI75Time frame: Week 12
  2. Proportion of subjects achieving sPGA0/1Time frame: Week 12

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Federal State Budgetary Educational Institution of Higher Education "Altai State Medical University" of the Ministry of Health of the Russian Federation

    Barnaul, Russia

  • State budgetary healthcare institution "Chelyabinsk Regional Clinical Dermatovenerological Dispensary"

    Chelyabinsk, Russia

  • Limited Liability Company "Health Azbuka Medical Center"

    Kazan', Russia

  • State Autonomous Healthcare Institution "Republic Clinical Dermatovenerologic Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor Ge"

    Kazan', Russia

  • State Autonomous Healthcare Institution "Kuzbass Clinical Dermatovenerological Dispensary"

    Kemerovo, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation

    Kirov, Russia

  • State budgetary healthcare institution "Clinical Dermatovenerologic Dispensary" of the Ministry of Health of the Krasnodar Territory

    Krasnodar, Russia

  • Federal State Autonomous Institution "National Medical Research Center for Children's Health" of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Federal State Budgetary Institution "State scientific centre of dermatovenerology and cosmetology" of the Ministry of health of Russian Federation, Nizhny Novgorod branch

    Nizhny Novgorod, Russia

  • Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation

    Saint Petersburg, Russia

  • Limited Liability Company "PiterKlinika"

    Saint Petersburg, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation

    Tomsk, Russia

  • Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University"

    Tomsk, Russia

  • State budgetary institution of the Sverdlovsk region "Ural Research Institute of Dermatovenereology and Immunopathology"

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.